mTOR/PI3K/Akt Signaling: Nutrient Sensing, Growth Control, and Therapeutic Targeting

# mTOR/PI3K/Akt Signaling: Nutrient Sensing, Growth Control, and Therapeutic Targeting

Research Use Only (RUO) — Not for Human or Animal Therapeutic Use

The PI3K/Akt/mTOR signaling axis is one of the most frequently dysregulated pathways in human cancer and metabolic disease, functioning as a master integrator of growth factor signals, nutrient availability, energy status, and cellular stress. Phosphoinositide 3-kinase (PI3K) generates the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the inner plasma membrane leaflet, recruiting Akt serine-threonine kinase through its pleckstrin homology (PH) domain. Fully activated Akt then phosphorylates hundreds of substrates controlling cell survival, proliferation, protein synthesis, autophagy, and metabolism. The mechanistic target of rapamycin (mTOR), operating in two structurally and functionally distinct complexes (mTORC1 and mTORC2), sits at the convergence of growth factor and nutrient inputs to coordinate anabolic programs with cellular resource availability. This review presents the structural basis of each signaling node, the regulatory architecture connecting them, and the research tools that enable precise pharmacological dissection of this pathway.

PI3K Family: Class IA Structure and Activation

Class IA PI3K Heterodimeric Architecture

Class IA PI3Ks are obligate heterodimers consisting of a p110 catalytic subunit (p110α, encoded by PIK3CA; p110β, PIK3CB; p110δ, PIK3CD) paired with a p85 regulatory subunit (p85α, PIK3R1; p85β, PIK3R2; p55α, p55γ, p50α — all encoded by PIK3R1 or PIK3R3). The p85 regulatory subunit contains two SH2 domains (N-SH2 and C-SH2) flanking an inter-SH2 (iSH2) coiled-coil domain, plus an N-terminal SH3 domain and a BH (BCR-homology) domain. In the basal state, the N-SH2 domain of p85 contacts and inhibits the p110α catalytic domain via the N-SH2 inhibitory interface — maintaining PI3K in a low-activity conformation.

Receptor tyrosine kinase (RTK) activation generates phosphotyrosine docking sites (e.g., pY740/pY751 on PDGFRβ; pY1172/pY1222 on EGFR) that are recognized by the SH2 domains of p85, releasing the N-SH2 inhibitory contact and simultaneously recruiting the PI3K heterodimer to the plasma membrane. RTK-bound PI3K gains access to its substrate PIP2 (phosphatidylinositol-4,5-bisphosphate) embedded in the inner leaflet, catalyzing the 3-OH phosphorylation to generate PIP3.

The p110α catalytic subunit contains five domains: an adaptor-binding domain (ABD) contacting the iSH2 of p85, a Ras-binding domain (RBD) that mediates direct interaction with Ras-GTP for allosteric activation, a C2 domain for membrane association, a helical domain, and the C-terminal kinase domain. PIK3CA hotspot mutations in human cancer (E545K, E542K in the helical domain; H1047R in the kinase domain) disrupt specific regulatory contacts within the p110α structure, constitutively activating PI3K independent of upstream RTK or Ras input.

PIP3 Generation and Membrane Recruitment

PIP3 has a half-life of seconds to minutes in activated cells, controlled by the opposing activities of PI3K (synthesis) and PTEN (phosphatase and tensin homolog, a lipid phosphatase that dephosphorylates PIP3 back to PIP2) and SHIP1/2 (SH2-domain-containing inositol polyphosphate 5-phosphatase, which generates PI(3,4)P2 from PIP3). PTEN is the second most frequently mutated tumor suppressor in human cancer after TP53 — PTEN loss allows unopposed PIP3 accumulation and constitutive Akt activation, driving oncogenesis in glioblastoma, prostate, endometrial, and breast cancers.

PIP3 acts as a second messenger by recruiting proteins with PH (pleckstrin homology) domains to the membrane. Key PH-domain proteins recruited by PIP3 include Akt, PDK1 (phosphoinositide-dependent kinase 1), GRP1/cytohesin, ARNO, Btk, and Rac-GEFs (Tiam1, Vav), making PIP3 a hub for multiple downstream signaling cascades.

Akt: Three-Step Activation Mechanism

PH Domain, Activation Loop, and Hydrophobic Motif

Akt exists as three isoforms (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ) with partially redundant but distinct functions: Akt1 is ubiquitously expressed and mediates survival; Akt2 is enriched in metabolic tissues and mediates insulin signaling; Akt3 is highly expressed in brain. All three share the same domain architecture: N-terminal PH domain, central kinase domain (with regulatory activation loop), and C-terminal hydrophobic motif (HM) containing S473 (Akt1 numbering).

Full Akt activation requires three sequential events:

Step 1 — PH domain-PIP3 engagement: The Akt PH domain binds PIP3 (and PI(3,4)P2) with high specificity. This interaction recruits Akt from cytoplasm to the plasma membrane and induces a conformational change that partially opens the kinase active site — a prerequisite for phosphorylation events.

Step 2 — PDK1 phosphorylation at T308 (activation loop): PDK1 is itself recruited to PIP3 via its own PH domain, concentrating it at the same membrane microdomains as Akt. PDK1 phosphorylates Akt at T308 within the activation loop, inducing full catalytic competency. PDK1 is a constitutively active kinase that phosphorylates multiple AGC kinase family members (S6K1, SGK, PKC isoforms, RSK) in addition to Akt.

Step 3 — mTORC2 phosphorylation at S473 (hydrophobic motif): Full Akt activation requires phosphorylation at S473 in the hydrophobic motif by mTORC2 (mTOR complex 2, containing rictor). S473 phosphorylation stabilizes the active Akt conformation and is required for phosphorylation of a subset of Akt substrates including FoxO1/3a and TSC2. Importantly, mTORC2 phosphorylates S473 most efficiently after T308 phosphorylation — establishing a sequential activation mechanism.

Major Akt Substrates and Cellular Outcomes

Akt phosphorylates >100 substrates at the consensus R-x-R-x-x-S/T-B motif (where B is a bulky hydrophobic residue). Key substrate groups:

Survival (anti-apoptotic): BAD (S136) → 14-3-3 sequestration → releases Bcl-XL; MDM2 (S166/S186) → nuclear entry → p53 ubiquitination/degradation; CASP9 (S196) → caspase-9 inhibition; FoxO1/3a (T24/T32, S256/S319, S319/S325) → nuclear exclusion → survival gene suppression, Bim/FasL suppression.

Cell cycle: GSK3β (S9) → inhibition → β-catenin stabilization + cyclin D/E stabilization; CDK inhibitor p21CIP1 (T145) and p27KIP1 (T157/T198) cytoplasmic retention → G1 restriction relief.

Protein synthesis (mTORC1 activation): TSC2 (T1462, S939, S981) → TSC1-TSC2 complex dissociation → Rheb-GTP accumulation → mTORC1 activation; PRAS40 (T246) → release from mTORC1 → mTORC1 activation.

Glucose metabolism: AS160/TBC1D4 (T642, T642) → GLUT4 vesicle translocation; PFK2/PFKFB2 (S483) → fructose-2,6-bisphosphate production → glycolysis enhancement; hexokinase II mitochondrial association.

mTOR Complex 1 (mTORC1): Nutrient and Growth Factor Integration

mTORC1 Composition and Architecture

mTORC1 is a ~1 MDa complex built around the mTOR kinase (FRAP1, a member of the PI3K-related kinase/PIKK family) with core components: raptor (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with Sec13 protein 8), PRAS40 (proline-rich Akt substrate 40 kDa), and DEPTOR (DEP-domain-containing mTOR-interacting protein). Raptor serves as the substrate-binding scaffold — it contains HEAT repeats that recognize the TOS (TOR signaling) motif present in mTORC1 substrates (S6K1: FDIDL; 4E-BP1: FEMDI). The cryo-EM structure of mTORC1 (Aylett et al., 2016) revealed a rhomboid particle with mTOR kinase sitting at the center, raptor forming the substrate-docking arch, and mLST8 stabilizing the kinase C-lobe.

Upstream Inputs to mTORC1: Growth Factors, Amino Acids, and Energy

mTORC1 integrates three major input classes:

Growth factor input (Akt → TSC1/2 → Rheb): The tuberous sclerosis complex 1/2 (TSC1 hamartin/TSC2 tuberin) dimer functions as a GTPase-activating protein (GAP) for the small GTPase Rheb (Ras homolog enriched in brain). TSC2 GAP activity maintains Rheb in the GDP-bound (inactive) form. Akt phosphorylation of TSC2 at multiple sites inhibits TSC1-TSC2 GAP activity, allowing Rheb to accumulate as Rheb-GTP. Rheb-GTP directly contacts and activates the mTOR kinase domain, stimulating mTORC1 catalytic activity.

Amino acid input (Ragulator/Rag GTPases): Amino acid availability — particularly leucine, arginine, and glutamine — controls mTORC1 lysosomal localization through the Ragulator complex and Rag GTPase heterodimers (RagA/B with RagC/D). Amino acid-loaded (active) Rag heterodimers (RagA/B-GTP bound to RagC/D-GDP) recruit mTORC1 to the lysosomal surface via raptor binding. The Ragulator complex (LAMTOR1-5) serves as the lysosomal anchor for the Rag GTPases. Once at the lysosome, mTORC1 encounters Rheb-GTP (which is constitutively lysosomal) for activation. Amino acid depletion causes Rag GDP-loading, mTORC1 lysosomal dissociation, and pathway inactivation — providing a mechanism for nutrient-sensing completely independent of growth factor/Akt inputs.

Energy input (AMPK → TSC2 + Raptor): Low ATP/high AMP activates AMPK (AMP-activated protein kinase), which phosphorylates TSC2 (S1387, T1271) to enhance TSC2 GAP activity toward Rheb (opposite of Akt effect) and directly phosphorylates raptor (S722, S792) creating 14-3-3 binding sites that dissociate raptor from mTOR — a dual braking mechanism on mTORC1 under energy stress.

mTORC1 Substrates: S6K1 and 4E-BP1

The two best-characterized mTORC1 substrates mediate translational control:

S6K1 (p70 ribosomal S6 kinase 1): mTORC1 phosphorylates S6K1 at T389 (the hydrophobic motif), which enables PDK1 to phosphorylate S6K1 at T229 (activation loop) — a sequential activation analogous to Akt. Active S6K1 phosphorylates: ribosomal S6 protein (S235/S236/S240/S244) → mRNA translation initiation enhancement; eIF4B (S422) → cap-dependent translation; SKAR (S1083) → pioneer round translation; eEF2K → elongation regulation; IRS-1 (S307, S636, S1101) → negative feedback on PI3K/Akt (see negative feedback below).

4E-BP1 (eIF4E-binding protein 1): mTORC1 phosphorylates 4E-BP1 at T37/T46 (priming sites), then S65/T70. Hyperphosphorylated 4E-BP1 dissociates from eIF4E, freeing eIF4E to join the eIF4F cap-binding complex (eIF4E + eIF4G + eIF4A). The eIF4F complex recruits the 43S pre-initiation complex to the 5' mRNA cap, initiating cap-dependent translation of mRNAs with structured 5' UTRs — particularly mRNAs encoding MYC, cyclin D1, VEGF, and HIF-1α. Rapamycin and rapalogs preferentially inhibit 4E-BP1 hyperphosphorylation (S65/T70) while sparing some S6K1 phosphorylation, making dual PI3K/mTOR inhibitors more effective at suppressing 4E-BP1-driven translation.

Negative Feedback Loops

mTORC1/S6K1 activation generates negative feedback on upstream PI3K/Akt:

S6K1 → IRS-1: S6K1 phosphorylates insulin receptor substrate-1 (IRS-1) at multiple serine residues (S307, S636/639, S1101), converting IRS-1 from a PI3K-activating scaffold to a PI3K interaction competitor. This serine-phosphorylated IRS-1 is degraded by the proteasome, attenuating PI3K activation by insulin/IGF-1.

mTORC1 → GRB10: mTORC1 phosphorylates the adaptor protein GRB10, which then binds insulin/IGF receptors and inhibits their tyrosine kinase activity toward IRS proteins — a second mechanism of mTORC1-driven insulin resistance.

These feedback loops mean that in cancer cells with activated PI3K/Akt, mTORC1 activity paradoxically reduces Akt activity, and treating with rapamycin can relieve S6K1-mediated IRS-1 suppression, leading to Akt hyperactivation — a pharmacological liability that motivated development of dual PI3K/mTOR inhibitors.

mTOR Complex 2 (mTORC2): Actin Cytoskeleton and Akt Hydrophobic Motif

mTORC2 shares the mTOR kinase and mLST8 with mTORC1 but substitutes rictor (rapamycin-insensitive companion of mTOR) for raptor, and includes mSin1 (mitogen-activated protein kinase-associated protein 1) and Protor1/2. Rictor and mSin1 are required for mTORC2 substrate recognition: mSin1's pleckstrin homology (PH) domain interacts with the kinase domain and is displaced by PIP3 engagement, providing a mechanism for PI3K-dependent mTORC2 activation (Liu P et al., 2015). mTORC2 substrates include: Akt S473 (hydrophobic motif, described above); PKCα (T638/T657) → actin cytoskeleton regulation; SGK1 (S422) → ion channel regulation and cell survival; PKCζ.

Unlike mTORC1, mTORC2 is not acutely sensitive to rapamycin (rapalogs do not acutely inhibit mTORC2), though prolonged rapamycin treatment (>24 h) depletes mTORC2 by sequestering mTOR away from rictor. This rapamycin insensitivity distinguishes mTORC2-regulated outputs (Akt-S473, SGK1, PKCα) from mTORC1-regulated outputs (S6K1-T389, 4E-BP1).

Research Tools and Pharmacological Modulators

Experimental Protocols

Protocol 1: PI3K/Akt/mTORC1 Pathway Activation Western Blot Panel

Objective: Quantify multi-node pathway activation in response to growth factor stimulation and pharmacological inhibition.

Materials: MCF-7 breast cancer cells or NIH-3T3 fibroblasts; EGF (100 ng/mL), IGF-1 (50 ng/mL), insulin (100 nM); phospho-antibody panel: pAkt-T308 (Cell Signaling #4056), pAkt-S473 (Cell Signaling #4060), pS6K1-T389 (Cell Signaling #9234), p4E-BP1-T37/46 (Cell Signaling #2855), p4E-BP1-S65 (Cell Signaling #9451), pS6-S235/236 (Cell Signaling #4858), pFoxO1-T24 (Cell Signaling #9464), pTSC2-T1462 (Cell Signaling #3617); total protein loading controls for each; PTEN antibody.

Protocol:

1. Seed 3 × 10⁵ cells/well in 6-well plates; grow 48 h; serum-starve 16 h.

2. Pre-treat with inhibitors 1 h: DMSO, rapamycin (20 nM), Torin1 (250 nM), GDC-0941 (1 µM), MK-2206 (1 µM), BEZ235 (500 nM).

3. Stimulate with EGF (100 ng/mL) or IGF-1 (50 ng/mL) for 20 min.

4. Lyse on ice in RIPA + PhosSTOP + cOmplete protease inhibitors; clarify 15,000 × g 10 min.

5. SDS-PAGE on 4–12% gradient; transfer; block 5% BSA; incubate phospho-antibodies overnight 4°C (1:1000).

6. Strip and reprobe for total protein; quantify by densitometry.

Expected phosphorylation pattern: EGF/IGF-1 stimulation activates pAkt-T308 (PDK1), pAkt-S473 (mTORC2), pTSC2-T1462, pS6K1-T389, pS6-S235/236, p4E-BP1-S65. Rapamycin selectively suppresses pS6K1-T389 and pS6-S235/236 but spares pAkt-T308/S473 (or slightly elevates pAkt due to IRS-1 feedback relief). Torin1 suppresses all mTORC1/2 substrates including pAkt-S473 and p4E-BP1-S65. GDC-0941 (PI3K inhibitor) suppresses pAkt-T308/S473 and all downstream signals. MK-2206 (Akt allosteric) blocks pFoxO1 and pTSC2 without affecting pAkt itself (allosteric mechanism blocks activity, not detected by phospho-specific antibodies at the inhibited site).

Protocol 2: mTORC1 Nutrient Sensing — Amino Acid Deprivation and Re-Stimulation

Objective: Demonstrate amino acid-dependent mTORC1 lysosomal localization and activity using leucine withdrawal/re-addition.

Materials: HeLa cells; RPMI minus amino acids (custom preparation or use EBSS); leucine (100 mM stock); LAMP1 antibody (lysosomal marker); raptor antibody (mTORC1 subunit); mTOR antibody; confocal microscope.

Protocol:

1. Seed HeLa cells on fibronectin-coated coverslips; grow to 70% confluence.

2. Wash 2× EBSS (balanced salt solution without amino acids); incubate in EBSS 2 h to deplete amino acids.

3. Re-stimulate with: EBSS alone (control), full RPMI (+all amino acids), EBSS + leucine (2 mM) for 20–60 min.

4. Fix 4% PFA 10 min; permeabilize 0.1% saponin 10 min; block 5% BSA.

5. Dual immunostain: anti-mTOR (rabbit, 1:200) + anti-LAMP1 (mouse, 1:500); Alexa 488 (mTOR) + Alexa 647 (LAMP1).

6. Confocal z-stack acquisition; calculate Pearson's correlation coefficient (mTOR/LAMP1 colocalization) using Fiji Coloc2 plugin.

7. Western blot parallel plates: pS6K1-T389, pS6-S235/236 as functional readout.

Expected results: Amino acid-replete cells: high mTOR/LAMP1 colocalization (Pearson's r ~0.7–0.9); pS6K1-T389 robust. Amino acid-depleted: mTOR dispersed from lysosomes (r ~0.2–0.4); pS6K1-T389 undetectable. Leucine re-addition: mTOR returns to lysosomal compartment within 10–20 min (r returns to 0.6–0.8); pS6K1 phosphorylation restored within 20–30 min.

Protocol 3: 4E-BP1 Phosphorylation State — Gel-Shift Analysis and Cap-Binding Assay

Objective: Distinguish rapamycin-insensitive (S65/T70) from rapamycin-sensitive (T37/46) 4E-BP1 phosphorylation and measure functional cap-binding complex assembly.

Materials: 4E-BP1 antibodies (total and phospho-specific); 7-methyl-GTP (m7GTP) Sepharose (Jena Bioscience or New England BioLabs); eIF4E antibody; eIF4G antibody; rapamycin; Torin1.

Protocol (Gel-shift):

1. Treat cells 4 h with rapamycin (20 nM), Torin1 (250 nM), or vehicle after EGF stimulation.

2. Run lysates on 15% urea-PAGE (not SDS-PAGE); 4E-BP1 migrates as multiple bands: α (hypo), β (intermediate), γ (hyper) based on phosphorylation state.

3. Blot with total 4E-BP1 antibody; quantify α:β:γ ratio. Rapamycin partially shifts from γ to β forms; Torin1 completely shifts to α (hypo).

Protocol (m7GTP cap pull-down):

1. Incubate 500 µg lysate with 20 µL m7GTP-Sepharose 2 h, 4°C rotating.

2. Wash 3× with lysis buffer; elute with 2× SDS loading buffer.

3. Western blot for eIF4E (loading control), eIF4G (cap complex assembly), 4E-BP1 (competes with eIF4G for eIF4E binding).

4. Quantify eIF4G/eIF4E ratio as cap complex assembly index; 4E-BP1/eIF4E ratio as cap-binding competition index.

Expected: Torin1 (mTOR catalytic inhibitor): complete loss of cap-bound eIF4G (4E-BP1 outcompetes eIF4G for eIF4E) and increase in cap-bound 4E-BP1 (hypophosphorylated 4E-BP1 binds eIF4E). Rapamycin: partial effect (suppresses S65/T70 but spares T37/46), partial cap-binding complex disruption. Growth factor stimulation (EGF): opposite of Torin1 — maximal cap-bound eIF4G, minimal cap-bound 4E-BP1.

Protocol 4: Akt Substrate Specificity — MK-2206 vs. Rapamycin Target Discrimination

Objective: Use selective inhibitors to assign phosphorylation events to Akt vs. mTORC1 kinase activity.

Materials: U87MG glioblastoma cells (PTEN-null, constitutively active Akt); MK-2206 (Akt allosteric, 1–10 µM); rapamycin (20 nM); Torin1 (250 nM); phospho-antibody panel as in Protocol 1 plus: pFoxO3a-T32 (Cell Signaling #9466), pGSK3β-S9 (Cell Signaling #9336), pPRAS40-T246 (Cell Signaling #2997).

Protocol:

1. Treat U87MG cells (no serum starvation needed due to constitutive PI3K/Akt activity) with: vehicle, MK-2206 (5 µM, 2 h), rapamycin (20 nM, 2 h), Torin1 (250 nM, 2 h), or combinations.

2. Western blot full panel.

3. Classify each phosphorylation event by inhibitor sensitivity.

Expected classification:

• •Direct Akt substrates (suppressed by MK-2206, not rapamycin): pFoxO1/3a, pGSK3β-S9, pPRAS40-T246, pTSC2-T1462.
• •mTORC1 substrates (suppressed by rapamycin/Torin1, not MK-2206): pS6K1-T389, pS6-S235/236, p4E-BP1-T37/46.
• •mTORC1/S6K1 substrates (suppressed by both, due to mTORC1→S6K1→substrate): pIRS-1-S636.
• •mTORC2 substrates (suppressed only by Torin1, not rapamycin, partial MK-2206 effect): pAkt-S473, pSGK1-S422.

This 2×2 inhibitor matrix cleanly assigns pathway attribution to each phosphorylation event.

Protocol 5: Autophagy Induction by mTORC1 Inhibition — LC3 Puncta and Flux Assay

Objective: Quantify autophagy induction upon mTORC1 inhibition using LC3B-II immunofluorescence and autophagic flux with bafilomycin A1.

Materials: HeLa-GFP-LC3 stable cells or U2OS; anti-LC3B antibody (Cell Signaling #3868); bafilomycin A1 (100 nM; vacuolar ATPase inhibitor that blocks lysosomal acidification and autophagosome-lysosome fusion); rapamycin; Torin1; ULK1 pS317 antibody (AMPK site); ULK1 pS757 antibody (mTORC1 site).

Protocol:

1. Treat cells: vehicle, rapamycin (100 nM, 4 h), Torin1 (250 nM, 4 h), EBSS starvation (4 h); ± bafilomycin A1 (100 nM, last 2 h of treatment).

2. Fix 4% PFA; permeabilize 0.1% Triton X-100; stain anti-LC3B (1:500) + DAPI.

3. Count LC3B puncta/cell in ≥50 cells/condition using Fiji (threshold, watershed, particle analysis).

4. Flux calculation: (LC3B puncta + BafA1) – (LC3B puncta – BafA1) = autophagic flux (new autophagosome formation rate).

5. Western blot parallel plates: LC3B-I (upper, ~16 kDa) → LC3B-II (lower, ~14 kDa) conversion; pULK1-S757 (mTORC1-driven inhibitory phosphorylation, suppressed by rapamycin/Torin1) vs. pULK1-S317 (AMPK-driven activating phosphorylation).

Expected: Rapamycin/Torin1 or EBSS starvation: pULK1-S757 loss → ULK1 activation → LC3B puncta increase (5–15-fold over vehicle); BafA1 addition to inhibitor-treated cells: further puncta accumulation (flux >vehicle + BafA1 condition). Western: LC3B-I → LC3B-II conversion (increased LC3B-II/LC3B-I ratio with Torin1; BafA1 further increases LC3B-II by blocking degradation).

Pathway Dysregulation in Disease Contexts

PIK3CA Mutations in Cancer

Hotspot mutations in PIK3CA (encoding p110α) — E542K, E545K (helical domain), and H1047R (kinase domain) — are among the most common oncogenic mutations, found in 18–40% of breast cancers, 26% of endometrial cancers, and 10–15% of colorectal cancers. The helical domain mutations (E542K, E545K) disrupt an inhibitory contact between the p110α helical domain and the p85 N-SH2 domain, constitutively activating PI3K independent of pY-mediated p85 relief. The kinase domain mutation H1047R repositions a loop in the kinase C-lobe to enhance membrane lipid substrate access. Both mutation classes bypass normal RTK requirement for PI3K activation.

PTEN Loss and Synthetic Lethality

PTEN deletion or inactivation (missense, frameshift, or epigenetic silencing) leads to unopposed PIP3 accumulation and constitutive Akt activity. PTEN-null tumors show mTORC1-driven negative feedback (S6K1 → IRS-1 serine phosphorylation → IRS-1 degradation), which can paradoxically reduce pAkt-T308 while maintaining pAkt-S473 and substrate phosphorylation. This feedback complexity explains why PTEN-null tumors show variable Akt-T308 phosphorylation despite constitutive PI3K activation. Synthetic lethality approaches in PTEN-null cells: PTEN-null tumors show heightened sensitivity to combined Akt + mTOR inhibition, and to DNA repair pathway inhibitors (PARP inhibitors) due to PTEN's nuclear role in DSB repair.

Tuberous Sclerosis Complex (TSC1/TSC2 Mutations) and Rapamycin Sensitivity

Loss-of-function mutations in TSC1 or TSC2 cause tuberous sclerosis complex — benign hamartomas in brain, kidney, skin, and heart driven by constitutive mTORC1 activation (Rheb-GTP accumulation without TSC1/2 GAP activity). TSC-associated tumors show exquisite sensitivity to rapamycin/rapalogs — one of the clearest genetic biomarker/drug relationships in the mTOR field. Everolimus (Afinitor) is approved for TSC-associated SEGA (subependymal giant cell astrocytoma) and renal angiomyolipomas.

Crosstalk with Other Pathways Discussed in This Series

PDGF-BB/PDGFR: PDGFRβ Y740/Y751 phospho-docking sites recruit PI3K p85 → PIP3 generation → Akt activation → TSC2 phosphorylation → mTORC1 activation. The PDGFR → PI3K → Akt axis is a major mitogenic and survival signaling axis in pericytes and fibroblasts.

IGF-1/IGF1R: IGF-1 receptor activates IRS-1/2 adaptors, which recruit PI3K p85 independently of direct pY-p85 interaction, providing high-gain PI3K activation relevant to muscle anabolism and cancer cell growth.

BMP-2/SMAD: BMP-2 activates PI3K/Akt through BMPR2-tail-associated mechanisms; Akt-driven GSK3β inhibition stabilizes β-catenin, creating BMP-PI3K-Wnt crosstalk in osteoblast specification.

mTOR and nutrient sensing in research contexts: The mTOR pathway serves as a readout of metabolic state in cultured cells — serum starvation, amino acid withdrawal, and energy depletion each attenuate specific mTOR complex activities, making pathway phosphorylation state a useful metabolic indicator in experimental models.

Summary

The PI3K/Akt/mTOR axis represents a highly integrated signal transduction network that converts diverse upstream inputs — growth factor receptor activation, amino acid availability, cellular energy status — into coordinated anabolic programs including protein synthesis, cell cycle progression, survival, and autophagy suppression. The structural basis for each signaling node is well-defined: PI3K p110/p85 heterodimer regulation, Akt PH-domain-dependent membrane recruitment with sequential T308/S473 phosphorylation, mTORC1 lysosomal localization controlled by Rag GTPases, and mTOR kinase domain catalysis of S6K1/4E-BP1.

The pharmacological toolkit — from allosteric rapamycin (mTORC1-selective) to catalytic Torin1 (mTORC1+mTORC2) to PI3K isoform-selective inhibitors (alpelisib, idelalisib) to Akt allosteric inhibitors (MK-2206) — enables precise node-by-node pathway dissection. Understanding the negative feedback loops (S6K1 → IRS-1, GRB10) is essential for interpreting inhibitor experiments correctly, as rapamycin paradoxically increases Akt-T308 phosphorylation and may enhance signaling through feedback-relieved upstream inputs.

---

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.

References

1. Cantley LC (2002). The phosphoinositide 3-kinase pathway. Science, 296(5573), 1655–1657. PMID: 12040186

2. Manning BD, Toker A (2017). AKT/PKB Signaling: Navigating the Network. Cell, 169(3), 381–405. PMID: 28431241

3. Saxton RA, Sabatini DM (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell, 168(6), 960–976. PMID: 28283069

4. Liu P, et al. (2015). Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nature Cell Biology, 17(5), 624–635. PMID: 25915124

5. Aylett CH, et al. (2016). Architecture of human mTOR complex 1. Science, 351(6268), 48–52. PMID: 26678875

6. Bar-Peled L, Sabatini DM (2014). Regulation of mTORC1 by amino acids. Trends in Cell Biology, 24(7), 400–406. PMID: 24560927

7. Guertin DA, Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell, 12(1), 9–22. PMID: 17613433

8. Thoreen CC, et al. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. Journal of Biological Chemistry, 284(12), 8023–8032. PMID: 19150980

9. Fruman DA, et al. (2017). The PI3K Pathway in Human Disease. Cell, 170(4), 605–635. PMID: 28802041

10. Zoncu R, Efeyan A, Sabatini DM (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell Biology, 12(1), 21–35. PMID: 21157483

11. Pollak M (2012). The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews Cancer, 12(3), 159–172. PMID: 22337149

12. Dibble CC, Manning BD (2013). Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nature Cell Biology, 15(6), 555–564. PMID: 23728461

13. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer, 2(7), 489–501. PMID: 12094235